<i>BRCA2</i> , <i>ATM</i> , and <i>CDK12</i> Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression
Evan W. Warner(Guardant (United States)), Alexander W. Wyatt(University of British Columbia), Kevin Beja(University of British Columbia), Arkhjamil Angeles, Steven Yip(University of Calgary), Gang Wang(Spinal Cord Injury BC), Arshia Beigi(BC Cancer Agency), Elena Schönlau(University of British Columbia), Daniel Khalaf(BC Cancer Agency), Amanda Wong(University of British Columbia), Gillian Vandekerkhove(University of British Columbia), Andrew J. Murtha(University of British Columbia), Simon Fu(BC Cancer Agency), Cameron Herberts(Natera (United States)), Nicolette M. Fonseca(University of British Columbia), Elie Ritch(University of British Columbia), Matti Annala(Tampere University), Kim N.(Asian Institute of Technology)
Cited by 87
Related Papers
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
The evolutionary history of lethal metastatic prostate cancer
|Nature|2015|1.4k
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2012|1.4k